The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
REZPEG in the treatment of plaque psoriasis: Results from a phase Ib trial
|
In inflammatory diseases such as psoriasis, Tregs are impaired and there is limited evidence on the therapeutic potential of Treg restoration.1 REZPEG selectively expands CD25bright regulatory T cells without increasing conventional T cells, suggesting it restores immune tolerance and balances immune responses, which are dysregulated in psoriasis.1 A phase Ib randomized, placebo-controlled study (NCT04119557) published in Nature Communicationsinvestigated REZPEG in 30 patients with chronic plaque psoriasis for 12 weeks, with follow-up to 19 weeks. Responders at Week 19 had follow-up through Week 48.
|
| Key learnings |
| Patients treated with REZPEG showed a LS mean improvement from baseline in PASI scores compared with placebo at Week 12 and Week 19 (44.5% vs 26.2% and 51.4% vs 19.9%, respectively), demonstrating sustained efficacy. |
| REZPEG was well tolerated, with TEAEs reported by 70.8% of patients. All except one TEAE were of mild-to-moderate severity, and no serious adverse events were reported. Injection site reactions were the most common treatment-related side effects. |
| REZPEG treatment led to long-term, treatment-free disease control, with a sustained decrease in psoriasis symptoms, highlighting the potential of REZPEG in providing prolonged remission and reducing treatment burden. |
| REZPEG has the potential to be an alternative to existing therapies for psoriasis, particularly for patients with inadequate responses to current biologics or immunosuppressants. |
Abbreviations: LS, least-squares; PASI, Psoriasis Area and Severity Index; REZPEG, rezpegaldesleukin; TEAE, treatment-emergent adverse event; Tregs, regulatory T cells.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content